- Home
- KIO vs ANL Comparison
KIO vs ANL Comparison
Compare KIO & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | KIO | ANL |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.1M | 406.5M |
| IPO Year | 2011 | 2022 |
Fundamental Metrics
Financial Performance| Metric | KIO | ANL |
|---|---|---|
| Price | $11.11 | $14.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 246.9K | ★ 350.7K |
| Earning Date | 01-01-0001 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.65 | $0.88 |
| 52 Week High | $12.83 | $13.00 |
Technical Indicators
Market Signals| Indicator | KIO | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 52.61 | 80.26 |
| Support Level | $10.66 | $1.36 |
| Resistance Level | $11.24 | N/A |
| Average True Range (ATR) | 0.17 | 1.38 |
| MACD | 0.05 | 0.70 |
| Stochastic Oscillator | 77.97 | 99.31 |
Price Performance
Historical ComparisonAbout KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.